Adage Capital Partners GP L.L.C. Sells 125,290 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Adage Capital Partners GP L.L.C. lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 73.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 44,349 shares of the biopharmaceutical company's stock after selling 125,290 shares during the quarter. Adage Capital Partners GP L.L.C.'s holdings in Regeneron Pharmaceuticals were worth $31,591,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of REGN. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $28,000. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares in the last quarter. Avalon Trust Co bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $36,000. Crowley Wealth Management Inc. bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $36,000. Finally, Private Wealth Management Group LLC lifted its stake in shares of Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 39 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN traded down $16.31 during mid-day trading on Thursday, reaching $582.45. The stock had a trading volume of 442,817 shares, compared to its average volume of 738,640. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The company has a market cap of $63.68 billion, a P/E ratio of 15.23, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals, Inc. has a 1 year low of $525.99 and a 1 year high of $1,211.20. The business's 50 day moving average price is $631.31 and its 200 day moving average price is $717.21.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $9.55 earnings per share. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.60%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Bernstein Bank lowered their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a research report on Wednesday. Piper Sandler lowered their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research report on Monday, January 27th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their price objective for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Finally, Guggenheim lowered their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating on the stock in a research report on Thursday. One analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $892.60.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.